Tyruko

Active Ingredient(s): Natalizumab-sztn
FDA Approved: * August 24, 2023
Pharm Company: * SANDOZ INC
Category: Immunosuppressive

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease.[3] It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin.[3] It is given by intravenous infusion every 28 days.[3] The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–b... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Related Brands

Drugs with the same active ingredients